Machine-Learning Approach for Modeling Myelosuppression Attributed to Nimustine Hydrochloride
Authors:
Open Access
- 1 December 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 2 (2) , 1-21
Abstract
A major adverse effect arising from nimustine hydrochloride (ACNU) therapy for brain tumors is myelosuppression. Because its timing and severity vary among individual patients, the ACNU dose level has been adjusted in an empiric manner at individual medical facilities. To our knowledge, ours is the first study to develop a machine-learning approach to estimate myelosuppression through analysis of patient factors before treatment and attempts to clarify the relationship between myelosuppression and hematopoietic stem cells from daily clinical data. Adverse effect prediction will allow ACNU dose adjustment for patients predicted to have decreases in blood cell counts and will enable focused follow-up of patients undergoing chemoradiotherapy. Patients were newly pathologically diagnosed with WHO grade 2 or 3 tumors and were treated with ACNU-based chemoradiotherapy. For detailed analysis of the timing and intensity of adverse effects in patients, we developed a data-weighted support vector machine (SVM) based on adverse event criteria (nadir-weighted SVM [NwSVM]). To evaluate the estimation accuracy of blood cell count dynamics, the determination coefficient (r2) between real and estimated data was calculated by three regression methods: polynomial, SVM, and NwSVM. Only the NwSVM-based regression enabled estimation of the dynamics of all blood cell types with high accuracy (mean r2 = 0.81). The mean timing of nadir arrival estimated using this regression was 35 days for platelets, 41 days for RBCs, 52 days for lymphocytes, 57 days for WBCs, and 62 days for neutrophils. The NwSVM can be used to predict myelosuppression and clearly depicts nadir timing differences between platelets and other blood cells.Keywords
This publication has 26 references indexed in Scilit:
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activityNeuro-Oncology, 2012
- FANCD1/BRCA2 Plays Predominant Role in the Repair of DNA Damage Induced by ACNU or TMZPLOS ONE, 2011
- Densely Interconnected Transcriptional Circuits Control Cell States in Human HematopoiesisCell, 2011
- Classification of brain tumor type and grade using MRI texture and shape in a machine learning schemeMagnetic Resonance in Medicine, 2009
- Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of ResponseJournal of Clinical Oncology, 2006
- Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic PotentialCell, 2005
- Financial time series prediction using least squares support vector machines within the evidence frameworkIEEE Transactions on Neural Networks, 2001
- Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiationActa Neurochirurgica, 1994
- Effects of ACNU and radiotherapy on malignant gliomaJournal of Neurosurgery, 1986